The therapeutic potential of FGF1 in diabetes treatment also provides valuable insights for its potential clinical application in MASLD, especially given the significant progress made with FGF21—another member of the FGF1 family—in MASLD therapy and drug development [22]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.